While, as expected, the AR pathway was universally measured as active in primary prostate cancer, AR pathway activity remained high in some castrate-resistant metastatic prostate cancers, possibly reflecting emergence of AR activating mutations (van de Stolpe et al., 2019a). The gene discussed is AR; the disease is prostate carcinoma.